Expression And Clinical Significance Of HCCR, MCM4, Ki-67and P53in Ovarian Serous Tumor

Objective To investigate the expression and clinical significance of the humancervical cancer oncogene(HCCR), minichromosome maintenance protein4(MCM4),Ki-67and p53in ovarian serous tumor, and further help to find new diagnosismolecular markers of ovarian serous tumor to guide diagnosis and treatment.Methods HCCR, MCM4, Ki-67and p53expression in86cases of serousadenocarcinoma,32cases of serous borderline tumors,38cases of benign seroustumors,31control grope were examined by immunohistochemistry (Elivision method),and combined with age, clinical stage, pathological grade and other clinical data wereanalyzed.Results1. In control group, benign serous tumors group, serous borderline tumorsgroup and serous adenocarcinoma group, the positive expression rate of HCCR were3.23%,21.05%,68.75%,88.37%respectively, gradually increased; lesions in serousborderline tumors group and serous adenocarcinoma group were significantlydifferent with the control grope (P<0.05). Serous adenocarcinoma group weresignificantly different with the benign serous tumors group (P<0.05). Serousadenocarcinoma group were significantly different with the serous borderline tumorsgroup (P<0.05). Serous borderline tumors group were significantly different with thebenign serous tumors group (P<0.05). Benign serous tumors group were notsignificantly different with the control group(P>0.05). Moderately positive expressionwere more common. Strong expression were seen in serous adenocarcinoma group.The expression of HCCR in the serous adenocarcinoma had no significant correlationwith patient’s age, clinical stage and pathological grades (P>0.05). The expression ofHCCR in the serous adenocarcinoma had significant correlation with metastasis (P<0.05).2. In control group, benign serous tumors group, serous borderline tumors group andserous adenocarcinoma group, the positive expression rate of MCM4were3.23%,21.05%,43.75%,79.07%respectively, gradually increased; lesions in serousadenocarcinoma group was significantly different with control group, benign seroustumors group, serous borderline tumors group (P<0.05). Serous borderline tumorsgroup were significantly different with the benign serous tumors group (P<0.05).Lesions in serous borderline tumors group was significantly different with the controlgrope (P<0.05). Benign serous tumors group were not significantly different with thecontrol group (P>0.05). The expression of MCM4in the serous adenocarcinoma hadno significant correlation with patient’s age, clinical stage,(P>0.05). The expressionof MCM4in the serous adenocarcinoma had significant correlation with metastasisand pathological grades (P＜0.05).3. In control group, benign serous tumors group, serous borderline tumors group andserous adenocarcinoma group, the positive expression rate of Ki-67were3.23%,15.79%,25.00%,53.49%respectively, gradually increased; lesions in serousadenocarcinoma group was significantly different with control group, benign seroustumors group (P<0.05). Lesions in serous adenocarcinoma group was significantlydifferent with serous borderline tumors group (P<0.05).Serous borderline tumorsgroup were not significantly different with the benign serous tumors group (P>0.05).Serous borderline tumors group were significantly different with the control group(P<0.05). Benign serous tumors group were not significantly different with thecontrol group (P>0.05). The expression of Ki-67in the serous adenocarcinoma hadno significant correlation with patient’s age (P>0.05). Ki-67in the serousadenocarcinoma had significant correlation with clinical stage, metastasis andpathological grades (P<0.05).4. In control group, benign serous tumors group, serous borderline tumors group andserous adenocarcinoma group, the positive expression rate of p53were3.23%,10.53%,31.25%,51.16%respectively, gradually increased; lesions in serousadenocarcinoma group was significantly different with control group, benign serous tumors group,(P<0.05). Lesions in serous adenocarcinoma group was notsignificantly different with serous borderline tumors group (P>0.05). Serousborderline tumors group were significantly different with the benign serous tumorsgroup (P<0.05). Serous borderline tumors group were significantly different with thecontrol group (P<0.05).Benign serous tumors group were not significantly differentwith the control group (P>0.05). The expression of p53in the serous adenocarcinomahad significant correlation with patient’s age (P<0.05), the expression of p53in theserous adenocarcinoma had no significant correlation with clinical stage, metastasisand pathological grades (P>0.05).5. There was significant association between MCM4and HCCR expression in serousadenocarcinoma (P<0.05). There was significant association between MCM4andKi-67expression in serous adenocarcinoma (P<0.05). There was significantassociation between HCCR and Ki-67expression in serous adenocarcinoma (P<0.05).There was no significant association between HCCR and p53, MCM4and p53, Ki-67and p53expression in serous adenocarcinoma (P>0.05).Conclusions1The positive expression rate of HCCR in benign serous tumorsgroup, serous borderline tumors group and serous adenocarcinoma group wasgradually increased. Lower differentiation, higher grading, more expression. SoHCCR may play important roles in occurrence and development of ovarian serousadenocarcinoma, and may become early diagnosis molecular markers of ovarianserous adenocarcinoma.2The positive expression rate of MCM4in serous borderline tumors group and serousadenocarcinoma group was higher than in control group. Higher grading, moreexpression. More metastasis, more expression. Lower differentiation, more expression.MCM4is useful for evaluating cell proliferative activity, help the diagnosis,metastasis and clinical evaluation, and may become early diagnosis molecularmarkers of ovarian serous adenocarcinoma.3The positive expression rate of Ki-67in benign serous tumors group, serousborderline tumors group and serous adenocarcinoma group were gradually increased.Lower differentiation, higher grading, more expression. Ki-67is useful for evaluating cell proliferative activity, help the clinical staging, pathological grading andmetastasis. The positive expression rate of MCM4in benign serous tumors group,serous borderline tumors group and serous adenocarcinoma group was higher thanKi-67. MCM4is better for the diagnosis of benign serous tumor, serous borderlinetumor and serous adenocarcinoma than Ki-67.4The positive expression rate of p53in serous borderline tumors group and serousadenocarcinoma group was higher than in control group. p53may become diagnosismolecular marker of ovarian serous adenocarcinoma. The positive expression rate ofp53in ovarian serous tumors was lower than HCCR and MCM4. p53is helpful fordiagnosis and pathological grading, need our more care.5The positive expression of HCCR in serous adenocarcinoma had significantassociation with MCM4and Ki-67. HCCR, MCM4and Ki-67may play importantroles in occurrence and development of ovarian serous adenocarcinoma. The positiveexpression of HCCR, MCM4and Ki-67in serous adenocarcinoma had no significantassociation with p53. They need our more care.